{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:06:42Z","timestamp":1793844402072,"version":"4.6.1"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00467-022-05520-6","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T15:37:19Z","timestamp":1651160239000},"page":"17-34","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Therapeutic trials in difficult to treat steroid sensitive nephrotic syndrome: challenges and future directions"],"prefix":"10.1007","volume":"38","author":[{"given":"Ashlene M.","family":"McKay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6313-5752","authenticated-orcid":false,"given":"Rulan S.","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Noone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"5520_CR1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-029249","volume":"148","author":"F Veltkamp","year":"2021","unstructured":"Veltkamp F, Rensma LR, Bouts AHM (2021) Incidence and relapse of idiopathic nephrotic syndrome: meta-analysis. Pediatrics 148:e2020029249. https:\/\/doi.org\/10.1542\/peds.2020-029249","journal-title":"Pediatrics"},{"key":"5520_CR2","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ekir.2019.12.015","volume":"5","author":"SA Carter","year":"2020","unstructured":"Carter SA, Mistry S, Fitzpatrick J, Banh T, Hebert D, Langlois V, Pearl RJ, Chanchlani R, Licht CPB, Radhakrishnan S, Brooke J, Reddon M, Levin L, Aitken-Menezes K, Noone D, Parekh RS (2020) Prediction of short- and long-term outcomes in childhood nephrotic syndrome. Kidney Int Rep 5:426\u2013434. https:\/\/doi.org\/10.1016\/j.ekir.2019.12.015","journal-title":"Kidney Int Rep"},{"key":"5520_CR3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/kisup.2012.9","volume":"2","author":"Kidney disease: improving global outcomes (KDIGO) Glomerulonephritis Work Group","year":"2012","unstructured":"Kidney disease: improving global outcomes (KDIGO) Glomerulonephritis Work Group (2012) KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Inter Suppl 2:139\u2013274","journal-title":"Kidney Inter Suppl"},{"key":"5520_CR4","doi-asserted-by":"publisher","first-page":"CD002290","DOI":"10.1002\/14651858.CD002290.pub5","volume":"4","author":"NG Larkins","year":"2020","unstructured":"Larkins NG, Liu ID, Willis NS, Craig JC, Hodson EM (2020) Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev 4:CD002290. https:\/\/doi.org\/10.1002\/14651858.CD002290.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"5520_CR5","doi-asserted-by":"publisher","first-page":"i106","DOI":"10.1093\/ndt\/gfw309","volume":"32","author":"MA Hladunewich","year":"2017","unstructured":"Hladunewich MA, Beanlands H, Herreshoff E, Troost JP, Maione M, Trachtman H, Poulton C, Nachman P, Modes MM, Hailperin M, Pitter R, Gipson DS (2017) Provider perspectives on treatment decision-making in nephrotic syndrome. Nephrol Dial Transplant 32:i106\u2013i114. https:\/\/doi.org\/10.1093\/ndt\/gfw309","journal-title":"Nephrol Dial Transplant"},{"key":"5520_CR6","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00431-017-2891-2","volume":"176","author":"G Desch\u00eanes","year":"2017","unstructured":"Desch\u00eanes G, Vivarelli M, Peruzzi L (2017) Variability of diagnostic criteria and treatment of idiopathic nephrotic syndrome across European countries. Eur J Pediatr 176:647\u2013654. https:\/\/doi.org\/10.1007\/s00431-017-2891-2","journal-title":"Eur J Pediatr"},{"key":"5520_CR7","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1007\/s00467-009-1282-y","volume":"24","author":"N MacHardy","year":"2009","unstructured":"MacHardy N, Miles PV, Massengill SF, Smoyer WE, Mahan JD, Greenbaum L, Massie S, Yao L, Nagaraj S, Lin JJ, Wigfall D, Trachtman H, Hu Y, Gipson DS (2009) Management patterns of childhood-onset nephrotic syndrome. Pediatr Nephrol 24:2193\u20132201. https:\/\/doi.org\/10.1007\/s00467-009-1282-y","journal-title":"Pediatr Nephrol"},{"key":"5520_CR8","doi-asserted-by":"publisher","first-page":"745444","DOI":"10.3389\/fped.2021.745444","volume":"9","author":"N Li","year":"2021","unstructured":"Li N, Hao J, Fu T, Du Y (2021) Evaluating the quality of life of 231 children with primary nephrotic syndrome and assessing parental awareness of the disease. Front Pediatr 9:745444. https:\/\/doi.org\/10.3389\/fped.2021.745444","journal-title":"Front Pediatr"},{"key":"5520_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-021-05401-4","author":"T Horinouchi","year":"2022","unstructured":"Horinouchi T, Nozu K, Iijima K (2022) An updated view of the pathogenesis of steroid-sensitive nephrotic syndrome. Pediatr Nephrol. https:\/\/doi.org\/10.1007\/s00467-021-05401-4","journal-title":"Pediatr Nephrol"},{"key":"5520_CR10","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1007\/s00467-020-04780-4","volume":"36","author":"S Dufek-Kamperis","year":"2021","unstructured":"Dufek-Kamperis S, Kleta R, Bockenhauer D, Gale D, Downie ML (2021) Novel insights in the genetics of steroid-sensitive nephrotic syndrome in childhood. Pediatr Nephrol 36:2165\u20132175. https:\/\/doi.org\/10.1007\/s00467-020-04780-4","journal-title":"Pediatr Nephrol"},{"key":"5520_CR11","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s00467-016-3456-8","volume":"32","author":"AM Karp","year":"2017","unstructured":"Karp AM, Gbadegesin RA (2017) Genetics of childhood steroid-sensitive nephrotic syndrome. Pediatr Nephrol 32:1481\u20131488. https:\/\/doi.org\/10.1007\/s00467-016-3456-8","journal-title":"Pediatr Nephrol"},{"key":"5520_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fped.2019.00008","volume":"7","author":"BM Lane","year":"2019","unstructured":"Lane BM, Cason R, Esezobor CI, Gbadegesin RA (2019) Genetics of childhood steroid sensitive nephrotic syndrome: an update. Front Pediatr 7:8. https:\/\/doi.org\/10.3389\/fped.2019.00008","journal-title":"Front Pediatr"},{"key":"5520_CR13","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1681\/ASN.2018101054","volume":"30","author":"S Dufek","year":"2019","unstructured":"Dufek S, Cheshire C, Levine AP, Trompeter RS, Issler N, Stubbs M, Mozere M, Gupta S, Klootwijk E, Patel V, Hothi D, Waters A, Webb H, Tullus K, Jenkins L, Godinho L, Levtchenko E, Wetzels J, Knoers N, Teeninga N, Nauta J, Shalaby M, Eldesoky S, Kari JA, Thalgahagoda S, Ranawaka R, Abeyagunawardena A, Adeyemo A, Kristiansen M, Gbadegesin R, Webb NJ, Gale DP, Stanescu HC, Kleta R, Bockenhauer D (2019) Genetic identification of two novel loci associated with steroid-sensitive nephrotic syndrome. J Am Soc Nephrol 30:1375\u20131384. https:\/\/doi.org\/10.1681\/ASN.2018101054","journal-title":"J Am Soc Nephrol"},{"key":"5520_CR14","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1681\/ASN.2017111185","volume":"29","author":"H Debiec","year":"2018","unstructured":"Debiec H, Dossier C, Letouze E, Gillies CE, Vivarelli M, Putler RK, Ars E, Jacqz-Aigrain E, Elie V, Colucci M, Debette S, Amouyel P, Elalaoui SC, Sefiani A, Dubois V, Simon T, Kretzler M, Ballarin J, Emma F, Sampson MG, Deschenes G, Ronco P (2018) Transethnic, genome-wide analysis reveals immune-related risk alleles and phenotypic correlates in pediatric steroid-sensitive nephrotic syndrome. J Am Soc Nephrol 29:2000\u20132013. https:\/\/doi.org\/10.1681\/ASN.2017111185","journal-title":"J Am Soc Nephrol"},{"key":"5520_CR15","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1681\/ASN.2017080859","volume":"29","author":"X Jia","year":"2018","unstructured":"Jia X, Horinouchi T, Hitomi Y, Shono A, Khor SS, Omae Y, Kojima K, Kawai Y, Nagasaki M, Kaku Y, Okamoto T, Ohwada Y, Ohta K, Okuda Y, Fujimaru R, Hatae K, Kumagai N, Sawanobori E, Nakazato H, Ohtsuka Y, Nakanishi K, Shima Y, Tanaka R, Ashida A, Kamei K, Ishikura K, Nozu K, Tokunaga K, Iijima K (2018) Strong association of the HLA-DR\/DQ locus with childhood steroid-sensitive nephrotic syndrome in the Japanese population. J Am Soc Nephrol 29:2189\u20132199. https:\/\/doi.org\/10.1681\/ASN.2017080859","journal-title":"J Am Soc Nephrol"},{"key":"5520_CR16","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.kint.2020.05.029","volume":"98","author":"X Jia","year":"2020","unstructured":"Jia X, Yamamura T, Gbadegesin R, McNulty MT, Song K, Nagano C, Hitomi Y, Lee D, Aiba Y, Khor SS, Ueno K, Kawai Y, Nagasaki M, Noiri E, Horinouchi T, Kaito H, Hamada R, Okamoto T, Kamei K, Kaku Y, Fujimaru R, Tanaka R, Shima Y, Research consortium on genetics of childhood idiopathic nephrotic syndrome in Japan (2020) Common risk variants in NPHS1 and TNFSF15 are associated with childhood steroid-sensitive nephrotic syndrome. Kidney Int 98:1308\u20131322. https:\/\/doi.org\/10.1016\/j.kint.2020.05.029","journal-title":"Kidney Int"},{"key":"5520_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1053\/j.ajkd.2017.10.013","volume":"71","author":"A Adeyemo","year":"2018","unstructured":"Adeyemo A, Esezobor C, Solarin A, Abeyagunawardena A, Kari JA, El Desoky S, Greenbaum LA, Kamel M, Kallash M, Silva C, Young A, Hunley TE, de Jesus-Gonzalez N, Srivastava T, Gbadegesin R (2018) HLA-DQA1 and APOL1 as risk loci for childhood-onset steroid-sensitive and steroid-resistant nephrotic syndrome. Am J Kidney Dis 71:399\u2013406. https:\/\/doi.org\/10.1053\/j.ajkd.2017.10.013","journal-title":"Am J Kidney Dis"},{"key":"5520_CR18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/s0140-6736(74)91880-7","volume":"2","author":"R Shalhoub","year":"1974","unstructured":"Shalhoub R (1974) Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 2:556\u2013560. https:\/\/doi.org\/10.1016\/s0140-6736(74)91880-7","journal-title":"Lancet"},{"key":"5520_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000183647","volume":"42","author":"C Lin","year":"1986","unstructured":"Lin C, Hsu H (1986) Histopathological and immunological studies in spontaneous remission of nephrotic syndrome after intercurrent measles infection. Nephron 42:10\u2013115. https:\/\/doi.org\/10.1159\/000183647","journal-title":"Nephron"},{"key":"5520_CR20","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1038\/sj.ki.5000341","volume":"69","author":"V Audard","year":"2006","unstructured":"Audard V, Larousserie F, Grimbert P, Abtahi M, Sotto JJ, Delmer A, Boue F, Nochy D, Brousse N, Delarue R, Remy P, Ronco P, Sahali D, Lang P, Hermine O (2006) Minimal change nephrotic syndrome and classical Hodgkin\u2019s lymphoma: report of 21 cases and review of the literature. Kidney Int 69:2251\u20132260. https:\/\/doi.org\/10.1038\/sj.ki.5000341","journal-title":"Kidney Int"},{"key":"5520_CR21","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1681\/ASN.V103529","volume":"10","author":"H Yap","year":"1999","unstructured":"Yap H, Cheung W, Murugasu B, Sim S, Seah C, Jordan S (1999) Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 10:529\u2013537. https:\/\/doi.org\/10.1681\/ASN.V103529","journal-title":"J Am Soc Nephrol"},{"key":"5520_CR22","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1053\/ajkd.2002.32769","volume":"39","author":"G Lama","year":"2002","unstructured":"Lama G, Luongo I, Tirino G, Borriello A, Carangio C, Salsano ME (2002) T-lymphocyte populations and cytokines in childhood nephrotic syndrome. Am J Kidney Dis 39:958\u2013965. https:\/\/doi.org\/10.1053\/ajkd.2002.32769","journal-title":"Am J Kidney Dis"},{"key":"5520_CR23","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s00467-009-1194-x","volume":"24","author":"XS Shao","year":"2009","unstructured":"Shao XS, Yang XQ, Zhao XD, Li Q, Xie YY, Wang XG, Wang M, Zhang W (2009) The prevalence of Th17 cells and FOXP3 regulate T cells (Treg) in children with primary nephrotic syndrome. Pediatr Nephrol 24:1683\u20131690. https:\/\/doi.org\/10.1007\/s00467-009-1194-x","journal-title":"Pediatr Nephrol"},{"key":"5520_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1365-2249.2011.04441.x","volume":"166","author":"R Bertelli","year":"2011","unstructured":"Bertelli R, Bodria M, Nobile M, Alloisio S, Barbieri R, Montobbio G, Patrone P, Ghiggeri GM (2011) Regulation of innate immunity by the nucleotide pathway in children with idiopathic nephrotic syndrome. Clin Exp Immunol 166:55\u201363. https:\/\/doi.org\/10.1111\/j.1365-2249.2011.04441.x","journal-title":"Clin Exp Immunol"},{"key":"5520_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111285","volume":"9","author":"R Bertelli","year":"2014","unstructured":"Bertelli R, Di Donato A, Cioni M, Grassi F, Ikehata M, Bonanni A, Rastaldi MP, Ghiggeri GM (2014) LPS nephropathy in mice is ameliorated by IL-2 independently of regulatory T cells activity. PLoS ONE 9:e111285. https:\/\/doi.org\/10.1371\/journal.pone.0111285","journal-title":"PLoS ONE"},{"key":"5520_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1681\/ASN.2007111244","volume":"20","author":"L Le Berre","year":"2009","unstructured":"Le Berre L, Bruneau S, Naulet J, Renaudin K, Buzelin F, Usal C, Smit H, Condamine T, Soulillou J-P, Dantal J (2009) Induction of T regulatory cells attenuates idiopathic nephrotic syndrome. J Am Soc Nephrol 20:57\u201367. https:\/\/doi.org\/10.1681\/ASN.2007111244","journal-title":"J Am Soc Nephrol"},{"key":"5520_CR27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1365-2249.2010.04160.x","volume":"161","author":"R Bertelli","year":"2010","unstructured":"Bertelli R, Trivelli A, Magnasco A, Cioni M, Bodria M, Carrea A, Montobbio G, Barbano G, Ghiggeri GM (2010) Failure of regulation results in an amplified oxidation burst by neutrophils in children with primary nephrotic syndrome. Clin Exp Immunol 161:151\u2013158. https:\/\/doi.org\/10.1111\/j.1365-2249.2010.04160.x","journal-title":"Clin Exp Immunol"},{"key":"5520_CR28","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00467-009-1119-8","volume":"24","author":"Y Hashimura","year":"2009","unstructured":"Hashimura Y, Nozu K, Kanegane H, Miyawaki T, Hayakawa A, Yoshikawa N, Nakanishi K, Takemoto M, Iijima K, Matsuo M (2009) Minimal change nephrotic syndrome associated with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Pediatr Nephrol 24:1181\u20131186. https:\/\/doi.org\/10.1007\/s00467-009-1119-8","journal-title":"Pediatr Nephrol"},{"key":"5520_CR29","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/cei.12675","volume":"183","author":"R Bertelli","year":"2016","unstructured":"Bertelli R, Bonanni A, Di Donato A, Cioni M, Ravani P, Ghiggeri GM (2016) Regulatory T cells and minimal change nephropathy: in the midst of a complex network. Clin Exp Immunol 183:166\u2013174. https:\/\/doi.org\/10.1111\/cei.12675","journal-title":"Clin Exp Immunol"},{"key":"5520_CR30","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1681\/asn.2015050523","volume":"27","author":"M Colucci","year":"2016","unstructured":"Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Rava L, Ruggiero B, Emma F, Vivarelli M (2016) B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol 27:1811\u20131822. https:\/\/doi.org\/10.1681\/asn.2015050523","journal-title":"J Am Soc Nephrol"},{"key":"5520_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s10157-017-1415-8","volume":"22","author":"M Sato","year":"2018","unstructured":"Sato M, Kamei K, Ogura M, Ishikura K, Ito S (2018) Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion. Clin Exp Nephrol 22:110\u2013116. https:\/\/doi.org\/10.1007\/s10157-017-1415-8","journal-title":"Clin Exp Nephrol"},{"key":"5520_CR32","doi-asserted-by":"publisher","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","volume":"3","author":"A Fornoni","year":"2011","unstructured":"Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW 3rd (2011) Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 3:85ra46. https:\/\/doi.org\/10.1126\/scitranslmed.3002231","journal-title":"Sci Transl Med"},{"key":"5520_CR33","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMc1401725","volume":"370","author":"B Basu","year":"2014","unstructured":"Basu B (2014) Ofatumumab for rituximab-resistant nephrotic syndrome. N Engl J Med 370:1268\u20131270. https:\/\/doi.org\/10.1056\/NEJMc1401725","journal-title":"New Engl J Med"},{"key":"5520_CR34","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1126\/science.aay6485","volume":"366","author":"MJ Mina","year":"2019","unstructured":"Mina MJ, Kula T, Leng Y, Li M, de Vries RD, Knip M, Siljander H, Rewers M, Choy DF, Wilson MS, Larman HB, Nelson AN, Griffin DE, de Swart RL, Elledge SJ (2019) Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science 366:599\u2013606. https:\/\/doi.org\/10.1126\/science.aay6485","journal-title":"Science"},{"key":"5520_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00467-015-3082-x","volume":"31","author":"JC Davin","year":"2016","unstructured":"Davin JC (2016) The glomerular permeability factors in idiopathic nephrotic syndrome. Pediatr Nephrol 31:207\u2013215. https:\/\/doi.org\/10.1007\/s00467-015-3082-x","journal-title":"Pediatr Nephrol"},{"key":"5520_CR36","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00467-013-2452-5","volume":"28","author":"RJ Maas","year":"2013","unstructured":"Maas RJ, Deegens JK, Wetzels JF (2013) Serum suPAR in patients with FSGS: trash or treasure? Pediatr Nephrol 28:1041\u20131048. https:\/\/doi.org\/10.1007\/s00467-013-2452-5","journal-title":"Pediatr Nephrol"},{"key":"5520_CR37","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1681\/asn.2021060794","volume":"33","author":"AJB Watts","year":"2022","unstructured":"Watts AJB, Keller KH, Lerner G, Rosales I, Collins AB, Sekulic M, Waikar SS, Chandraker A, Riella LV, Alexander MP, Troost JP, Chen J, Fermin D, Yee JL, Sampson MG, Beck LH Jr, Henderson JM, Greka A, Rennke HG, Weins A (2022) Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J Am Soc Nephrol 33:238\u2013252. https:\/\/doi.org\/10.1681\/asn.2021060794","journal-title":"J Am Soc Nephrol"},{"key":"5520_CR38","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s00467-006-0316-y","volume":"22","author":"S Takahashi","year":"2007","unstructured":"Takahashi S, Wada N, Murakami H, Funaki S, Inagaki T, Harada K, Nagata M (2007) Triggers of relapse in steroid-dependent and frequently relapsing nephrotic syndrome. Pediatr Nephrol 22:232\u2013236. https:\/\/doi.org\/10.1007\/s00467-006-0316-y","journal-title":"Pediatr Nephrol"},{"key":"5520_CR39","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/s0022-3476(86)80876-9","volume":"108","author":"N MacDonald","year":"1986","unstructured":"MacDonald N, Wolfish N, McLaine P, Phipps P, Rossier E (1986) Role of respiratory viruses in exacerbations of primary nephrotic syndrome. J Pediatr 108:378\u2013382. https:\/\/doi.org\/10.1016\/s0022-3476(86)80876-9","journal-title":"J Pediatr"},{"key":"5520_CR40","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s00467-014-2860-1","volume":"29","author":"C Dossier","year":"2014","unstructured":"Dossier C, Sellier-Leclerc AL, Rousseau A, Michel Y, Gautheret-Dejean A, Englender M, Madhi F, Charbit M, Ulinski T, Simon T, Jacqz-Aigrain E, Desch\u00eanes G (2014) Prevalence of herpes viruses at onset of idiopathic nephrotic syndrome. Pediatr Nephrol 29:2325\u20132331. https:\/\/doi.org\/10.1007\/s00467-014-2860-1","journal-title":"Pediatr Nephrol"},{"key":"5520_CR41","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/pr.2016.200","volume":"81","author":"C Dossier","year":"2017","unstructured":"Dossier C, Jamin A, Deschenes G (2017) Idiopathic nephrotic syndrome: the EBV hypothesis. Pediatr Res 81:233\u2013239. https:\/\/doi.org\/10.1038\/pr.2016.200","journal-title":"Pediatr Res"},{"key":"5520_CR42","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1053\/j.ajkd.2009.03.019","volume":"54","author":"M Abdel-Hafez","year":"2009","unstructured":"Abdel-Hafez M, Shimada M, Lee P, Johnson R, Garin E (2009) Idiopathic nephrotic syndrome and atopy: is there a common link? Am J Kidney Dis 54:945\u2013953. https:\/\/doi.org\/10.1053\/j.ajkd.2009.03.019","journal-title":"Am J Kidney Dis"},{"key":"5520_CR43","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/s0140-6736(77)92603-4","volume":"1","author":"D Sandberg","year":"1977","unstructured":"Sandberg D, Bernstein C, McIntosh R, Carr R, Strauss J (1977) Severe steroid-responsive nephrosis associated with hypersensitivity. Lancet 1:388\u2013391. https:\/\/doi.org\/10.1016\/s0140-6736(77)92603-4","journal-title":"Lancet"},{"issue":"251\u2013257","key":"5520_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2018.12.048","volume":"208","author":"SS Riar","year":"2019","unstructured":"Riar SS, Banh THM, Borges K, Subbarao P, Patel V, Vasilevska-Ristovska J, Chanchlani R, Hussain-Shamsy N, Noone D, Hebert D, Licht CPB, Langlois V, Pearl RJ, Parekh RS (2019) Prevalence of asthma and allergies and risk of relapse in childhood nephrotic syndrome: insight into nephrotic syndrome cohort. J Pediatr 208(251\u2013257):e251. https:\/\/doi.org\/10.1016\/j.jpeds.2018.12.048","journal-title":"J Pediatr"},{"key":"5520_CR45","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s0140-6736(89)91266-x","volume":"333","author":"MA Lewis","year":"1989","unstructured":"Lewis MA, Baildom EM, Davis N, Houtston IB, Pstlethwaite RJ (1989) Nephrotic syndrome: from toddlers to twenties. Lancet 333:255\u2013259. https:\/\/doi.org\/10.1016\/s0140-6736(89)91266-x","journal-title":"Lancet"},{"key":"5520_CR46","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/ajkd.2003.50116","volume":"41","author":"F Fakhouri","year":"2003","unstructured":"Fakhouri F, Bocquet N, Taupin P, Presne C, Gagnadoux MF, Landais P, Lesavre P, Chauveau D, Knebelmann B, Broyer M, Grunfeld JP, Niaudet P (2003) Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am J Kidney Dis 41:550\u2013557. https:\/\/doi.org\/10.1053\/ajkd.2003.50116","journal-title":"Am J Kidney Dis"},{"key":"5520_CR47","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/s0140-6736(85)91387-x","volume":"325","author":"RS Trompeter","year":"1985","unstructured":"Trompeter RS, Lloyd BW, Hicks J, White RH, Cameron JS (1985) Long-term outcome for children with minimal-change nephrotic syndrome. Lancet 325:368\u2013370. https:\/\/doi.org\/10.1016\/s0140-6736(85)91387-x","journal-title":"Lancet"},{"key":"5520_CR48","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jpeds.2005.03.050","volume":"147","author":"EM Ruth","year":"2005","unstructured":"Ruth EM, Kemper MJ, Leumann EP, Laube GF, Neuhaus TJ (2005) Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr 147:202\u2013207. https:\/\/doi.org\/10.1016\/j.jpeds.2005.03.050","journal-title":"J Pediatr"},{"key":"5520_CR49","doi-asserted-by":"publisher","first-page":"166","DOI":"10.5414\/cn108044","volume":"81","author":"P Skrzypczyk","year":"2014","unstructured":"Skrzypczyk P, Panczyk-Tomaszewska M, Roszkowska-Blaim M, Wawer Z, Bienias B, Zajgzkowska M, Kilis-Pstrusinska K, Jakubowska A, Szczepaniak M, Pawlak-Bratkowska M, Tkaczyk M (2014) Long-term outcomes in idiopathic nephrotic syndrome: from childhood to adulthood. Clin Nephrol 81:166\u2013173. https:\/\/doi.org\/10.5414\/cn108044","journal-title":"Clin Nephrol"},{"key":"5520_CR50","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s004670050489","volume":"12","author":"N Kabuki","year":"1998","unstructured":"Kabuki N, Okugawa T, Hayakawa H, Tomizawa S, Kasahara T, Uchiyama M (1998) Influence of age at onset on the outcome of steroid-sensitive nephrotic syndrome. Pediatr Nephrol 12:467\u2013470. https:\/\/doi.org\/10.1007\/s004670050489","journal-title":"Pediatr Nephrol"},{"key":"5520_CR51","doi-asserted-by":"publisher","first-page":"CD001533","DOI":"10.1002\/14651858.CD001533.pub4","volume":"4","author":"EM Hodson","year":"2007","unstructured":"Hodson EM, Willis NS, Craig JC (2007) Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 4:CD001533. https:\/\/doi.org\/10.1002\/14651858.CD001533.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"5520_CR52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00467-021-04985-1","volume":"37","author":"MT Christian","year":"2022","unstructured":"Christian MT, Maxted AP (2022) Optimizing the corticosteroid dose in steroid-sensitive nephrotic syndrome. Pediatr Nephrol 37:37\u201347. https:\/\/doi.org\/10.1007\/s00467-021-04985-1","journal-title":"Pediatr Nephrol"},{"key":"5520_CR53","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/ki.2014.260","volume":"87","author":"N Yoshikawa","year":"2015","unstructured":"Yoshikawa N, Nakanishi K, Sako M, Oba MS, Mori R, Ota E, Ishikura K, Hataya H, Honda M, Ito S, Shima Y, Kaito H, Nozu K, Nakamura H, Igarashi T, Ohashi Y, Iijima K (2015) A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int 87:225\u2013232. https:\/\/doi.org\/10.1038\/ki.2014.260","journal-title":"Kidney Int"},{"key":"5520_CR54","first-page":"380","volume":"331","author":"Arbeitsgemeinschaft fur Padiatrische Nephrologie (APN)","year":"1988","unstructured":"Arbeitsgemeinschaft fur Padiatrische Nephrologie (APN) (1988) Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome. Lancet 331:380\u2013383","journal-title":"Lancet"},{"key":"5520_CR55","doi-asserted-by":"publisher","first-page":"CD001533","DOI":"10.1002\/14651858.CD001533.pub6","volume":"8","author":"D Hahn","year":"2020","unstructured":"Hahn D, Samuel SM, Willis NS, Craig JC, Hodson EM (2020) Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 8:CD001533. https:\/\/doi.org\/10.1002\/14651858.CD001533.pub6","journal-title":"Cochrane Database Syst Rev"},{"key":"5520_CR56","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/s0272-6386(03)00346-9","volume":"41","author":"M Hiraoka","year":"2003","unstructured":"Hiraoka M, Tsukahara H, Matsubara K, Tsurusawa M, Takeda N, Haruki S, Hayashi S, Ohta K, Momoi T, Ohshima Y, Suganuma N, Mayumi M (2003) A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children. Am J Kidney Dis 41:1155\u20131162. https:\/\/doi.org\/10.1016\/s0272-6386(03)00346-9","journal-title":"Am J Kidney Dis"},{"key":"5520_CR57","doi-asserted-by":"publisher","first-page":"e024882","DOI":"10.1136\/bmjopen-2018-024882","volume":"8","author":"R Ehren","year":"2018","unstructured":"Ehren R, Benz MR, Doetsch J, Fichtner A, Gellermann J, Haffner D, Hocker B, Hoyer PF, Kastner B, Kemper MJ, Konrad M, Luntz S, Querfeld U, Sander A, Toenshoff B, Weber LT, Gesellschaft fur PadiatrischeNephrologie (GPN) (2018) Initial treatment of steroid-sensitive idiopathic nephrotic syndrome in children with mycophenolate mofetil versus prednisone: protocol for a randomised, controlled, multicentre trial (INTENT study). BMJ Open 8:e024882. https:\/\/doi.org\/10.1136\/bmjopen-2018-024882","journal-title":"BMJ Open"},{"key":"5520_CR58","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2215\/cjn.06180519","volume":"15","author":"NR Medjeral-Thomas","year":"2020","unstructured":"Medjeral-Thomas NR, Lawrence C, Condon M, Sood B, Warwicker P, Brown H, Pattison J, Bhandari S, Barratt J, Turner N, Cook HT, Levy JB, Lightstone L, Pusey C, Galliford J, Cairns TD, Griffith M (2020) Randomized, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: a multicenter, randomized, controlled trial. Clin J Am Soc Nephrol 15:209\u2013218. https:\/\/doi.org\/10.2215\/cjn.06180519","journal-title":"Clin J Am Soc Nephrol"},{"key":"5520_CR59","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1056\/NEJM197609302951402","volume":"295","author":"W Grupe","year":"1976","unstructured":"Grupe W, Makker S, Ingelfinger J (1976) Chlorambucil treatment of frequently relapsing nephrotic syndrome. N Engl J Med 295:746\u2013749. https:\/\/doi.org\/10.1056\/NEJM197609302951402","journal-title":"N Engl J Med"},{"key":"5520_CR60","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1056\/NEJM198202253060803","volume":"306","author":"Arbeitsgemeinschaft fur Padiatrische Nephrologie","year":"1982","unstructured":"Arbeitsgemeinschaft fur Padiatrische Nephrologie (1982) Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. N Engl J Med 306:451\u2013454. https:\/\/doi.org\/10.1056\/NEJM198202253060803","journal-title":"N Engl J Med"},{"key":"5520_CR61","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/s0140-6736(70)90108-x","volume":"296","author":"T Barratt","year":"1970","unstructured":"Barratt T, Soothill J (1970) Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Lancet 296:479\u2013482. https:\/\/doi.org\/10.1016\/s0140-6736(70)90108-x","journal-title":"Lancet"},{"key":"5520_CR62","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/s0022-3476(73)80585-2","volume":"82","author":"J Chiu","year":"1973","unstructured":"Chiu J, McLaine P, Drummond K (1973) A controlled prospective study of cyclophosphamide in relapsing, corticosteroid-responsive, minimal-lesion nephrotic syndrome in childhood. J Pediatr 82:607\u2013613. https:\/\/doi.org\/10.1016\/s0022-3476(73)80585-2","journal-title":"J Pediatr"},{"key":"5520_CR63","doi-asserted-by":"crossref","unstructured":"(1974) Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children. Lancet 304:423\u2013427","DOI":"10.1016\/S0140-6736(74)91814-5"},{"key":"5520_CR64","doi-asserted-by":"crossref","unstructured":"(1991) Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. British Association for Paediatric Nephrology. Lancet 337:1555\u20131557","DOI":"10.1016\/0140-6736(91)93257-A"},{"key":"5520_CR65","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000187855","volume":"66","author":"U Dayal","year":"1994","unstructured":"Dayal U, Dayal A, Shastry J, Raghupathy P (1994) Use of levamisole in maintaining remission in steroid-sensitive nephrotic syndrome in children. Nephron 66:408\u2013412. https:\/\/doi.org\/10.1159\/000187855","journal-title":"Nephron"},{"key":"5520_CR66","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1007\/s00467-005-1943-4","volume":"20","author":"AF Donia","year":"2005","unstructured":"Donia AF, Ammar HM, El-Agroudy Ael-B, Moustafa Fel-H, Sobh MA (2005) Long-term results of two unconventional agents in steroid-dependent nephrotic children. Pediatr Nephrol 20:1420\u20131425. https:\/\/doi.org\/10.1007\/s00467-005-1943-4","journal-title":"Pediatr Nephrol"},{"key":"5520_CR67","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00467-005-2080-9","volume":"21","author":"K Al-Saran","year":"2006","unstructured":"Al-Saran K, Mirza K, Al-Ghanam G, Abdelkarim M (2006) Experience with levamisole in frequently relapsing, steroid-dependent nephrotic syndrome. Pediatr Nephrol 21:201\u2013205. https:\/\/doi.org\/10.1007\/s00467-005-2080-9","journal-title":"Pediatr Nephrol"},{"key":"5520_CR68","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.kint.2017.08.011","volume":"93","author":"MP Gruppen","year":"2018","unstructured":"Gruppen MP, Bouts AH, Jansen-van der Weide MC, Merkus MP, Zurowska A, Maternik M, Massella L, Emma F, Niaudet P, Cornelissen EAM, Schurmans T, Raes A, van de Walle J, van Dyck M, Gulati A, Bagga A, Davin JC (2018) A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome. Kidney Int 93:510\u2013518. https:\/\/doi.org\/10.1016\/j.kint.2017.08.011","journal-title":"Kidney Int"},{"key":"5520_CR69","first-page":"1326","volume":"8","author":"C Ponticelli","year":"1993","unstructured":"Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, Zacchello G, Confalonieri R, Altieri P et al (1993) Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant 8:1326\u20131332","journal-title":"Nephrol Dial Transplant"},{"key":"5520_CR70","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1681\/asn.2012121200","volume":"24","author":"J Gellermann","year":"2013","unstructured":"Gellermann J, Weber L, Pape L, T\u00f6nshoff B, Hoyer P, Querfeld U (2013) Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol 24:1689\u20131697. https:\/\/doi.org\/10.1681\/asn.2012121200","journal-title":"J Am Soc Nephrol"},{"key":"5520_CR71","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00467-008-0899-6","volume":"23","author":"EM Dorresteijn","year":"2008","unstructured":"Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, Nauta J, Hop WC, van der Heijden AJ (2008) Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol 23:2013\u20132020. https:\/\/doi.org\/10.1007\/s00467-008-0899-6","journal-title":"Pediatr Nephrol"},{"key":"5520_CR72","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.kint.2018.08.039","volume":"95","author":"A Sinha","year":"2019","unstructured":"Sinha A, Puraswani M, Kalaivani M, Goyal P, Hari P, Bagga A (2019) Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial. Kidney Int 95:210\u2013218. https:\/\/doi.org\/10.1016\/j.kint.2018.08.039","journal-title":"Kidney Int"},{"key":"5520_CR73","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1681\/ASN.2021050643","volume":"33","author":"K Iijima","year":"2022","unstructured":"Iijima K, Sako M, Oba M, Tanaka S, Hamada R, Sakai T, Ohwada Y, Ninchoji T, Yamamura T, Machida H, Shima Y, Tanaka R, Kaito H, Araki Y, Morohashi T, Kumagai N, Gotoh Y, Ikezumi Y, Kubota T, Kamei K, Fujita N, Ohtsuka Y, Okamoto T, Yamada T, Tanaka E, Shimizu M, Horinochi T, Konishi A, Omori T, Nakanishi K, Ishikura K, Ito S, Nakamura H, Nozu K, Japanese Study Group of Kidney Disease in Children (2022) Mycophenolate mofetil after rituximab for childhood-onset complicated frequently-relapsing or steroid-dependent nephrotic syndrome. J Am Soc Nephrol 33:401\u2013419. https:\/\/doi.org\/10.1681\/ASN.2021050643","journal-title":"J Am Soc Nephrol"},{"key":"5520_CR74","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2215\/cjn.09421010","volume":"6","author":"P Ravani","year":"2011","unstructured":"Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E, Scozzola F, Pasini A, Dallera N, Sica F, Belingheri M, Scolari F, Ghiggeri GM (2011) Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 6:1308\u20131315. https:\/\/doi.org\/10.2215\/cjn.09421010","journal-title":"Clin J Am Soc Nephrol"},{"key":"5520_CR75","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/s0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273\u20131281. https:\/\/doi.org\/10.1016\/s0140-6736(14)60541-9","journal-title":"Lancet"},{"key":"5520_CR76","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1007\/s00467-017-3718-0","volume":"32","author":"K Kamei","year":"2017","unstructured":"Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, Kaito H, Nakanishi K, Ohtomo Y, Miura K, Takahashi S, Morimoto T, Kubota W, Ito S, Nakamura H, Iijima K (2017) Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatr Nephrol 32:2071\u20132078. https:\/\/doi.org\/10.1007\/s00467-017-3718-0","journal-title":"Pediatr Nephrol"},{"key":"5520_CR77","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/asn.2014080799","volume":"26","author":"P Ravani","year":"2015","unstructured":"Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini A, Montini G, Edefonti A, Belingheri M, De Giovanni D, Barbano G, Degl\u2019Innocenti L, Scolari F, Murer L, Reiser J, Fornoni A, Ghiggeri GM (2015) Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol 26:2259\u20132266. https:\/\/doi.org\/10.1681\/asn.2014080799","journal-title":"J Am Soc Nephrol"},{"key":"5520_CR78","doi-asserted-by":"publisher","first-page":"e13157","DOI":"10.1097\/md.0000000000013157","volume":"97","author":"YH Ahn","year":"2018","unstructured":"Ahn YH, Kim SH, Han KH, Choi HJ, Cho H, Lee JW, Shin JI, Cho MH, Lee JH, Park YS, Ha IS, Cheong HI, Kim SY, Lee SJ, Kang HG (2018) Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea. Medicine 97:e13157. https:\/\/doi.org\/10.1097\/md.0000000000013157","journal-title":"Medicine"},{"key":"5520_CR79","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaut.2017.10.006","volume":"88","author":"A Boumediene","year":"2018","unstructured":"Boumediene A, Vachin P, Sendeyo K, Oniszczuk J, Zhang SY, Henique C, Pawlak A, Audard V, Ollero M, Guigonis V, Sahali D (2018) NEPHRUTIX: a randomized, double-blind, placebo vs rituximab-controlled trial assessing T-cell subset changes in minimal change nephrotic syndrome. J Autoimmun 88:91\u2013102. https:\/\/doi.org\/10.1016\/j.jaut.2017.10.006","journal-title":"J Autoimmun"},{"key":"5520_CR80","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","volume":"172","author":"B Basu","year":"2018","unstructured":"Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS, Schaefer F (2018) Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial. JAMA Pediatr 172:757\u2013764. https:\/\/doi.org\/10.1001\/jamapediatrics.2018.1323","journal-title":"JAMA Pediatr"},{"key":"5520_CR81","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jamapediatrics.2020.6150","volume":"175","author":"P Ravani","year":"2021","unstructured":"Ravani P, Lugani F, Drovandi S, Caridi G, Angeletti A, Ghiggeri GM (2021) Rituximab vs low-dose mycophenolate mofetil in recurrence of steroid-dependent nephrotic syndrome in children and young adults: a randomized clinical trial. JAMA Pediatr 175:631\u2013632. https:\/\/doi.org\/10.1001\/jamapediatrics.2020.6150","journal-title":"JAMA Pediatr"},{"key":"5520_CR82","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1681\/ASN.2021040561","volume":"32","author":"P Ravani","year":"2021","unstructured":"Ravani P, Colucci M, Bruschi M, Vivarelli M, Cioni M, DiDonato A, Cravedi P, Lugani F, Antonini F, Prunotto M, Emma F, Angeletti A, Ghiggeri GM (2021) Human or chimeric monoclonal anti-CD20 antibodies for children with nephrotic syndrome: a superiority randomized trial. J Am Soc Nephrol 32:2652\u20132663. https:\/\/doi.org\/10.1681\/ASN.2021040561","journal-title":"J Am Soc Nephrol"},{"key":"5520_CR83","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1046\/j.1523-1755.2000.00168.x","volume":"58","author":"K Yoshioka","year":"2000","unstructured":"Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, Tanizawa T, Wada H, Maki S (2000) A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int 58:317\u2013324. https:\/\/doi.org\/10.1046\/j.1523-1755.2000.00168.x","journal-title":"Kidney Int"},{"key":"5520_CR84","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1056\/NEJM198202253060803","volume":"306","author":"Arbeitsgemeinschaft f\u00fcr P\u00e4diatrische Nephrologie","year":"1982","unstructured":"Arbeitsgemeinschaft f\u00fcr P\u00e4diatrische Nephrologie (1982) Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. N Engl J Med 306:451\u2013454. https:\/\/doi.org\/10.1056\/NEJM198202253060803","journal-title":"N Engl J Med"},{"key":"5520_CR85","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.2215\/CJN.00380116","volume":"11","author":"TH Banh","year":"2016","unstructured":"Banh TH, Hussain-Shamsy N, Patel V, Vasilevska-Ristovska J, Borges K, Sibbald C, Lipszyc D, Brooke J, Geary D, Langlois V, Reddon M, Pearl R, Levin L, Piekut M, Licht CP, Radhakrishnan S, Aitken-Menezes K, Harvey E, Hebert D, Piscione TD, Parekh RS (2016) Ethnic differences in incidence and outcomes of childhood nephrotic syndrome. Clin J Am Soc Nephrol 11:1760\u20131768. https:\/\/doi.org\/10.2215\/CJN.00380116","journal-title":"Clin J Am Soc Nephrol"},{"key":"5520_CR86","doi-asserted-by":"publisher","first-page":"E424","DOI":"10.9778\/cmajo.20160078","volume":"5","author":"SM Samuel","year":"2017","unstructured":"Samuel SM, Flynn R, Zappitelli M, Dart A, Parekh R, Pinsk M, Mammen C, Wade A, Scott SD (2017) Factors influencing practice variation in the management of nephrotic syndrome: a qualitative study of pediatric nephrology care providers. CMAJ Open 5:E424\u2013E430. https:\/\/doi.org\/10.9778\/cmajo.20160078","journal-title":"CMAJ Open"},{"key":"5520_CR87","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.2215\/CJN.00320116","volume":"11","author":"S Tellier","year":"2016","unstructured":"Tellier S, Dallocchio A, Guigonis V, Saint-Marcoux F, Llanas B, Ichay L, Bandin F, Godron A, Morin D, Brochard K, Gandia P, Bouchet S, Marquet P, Decramer S, Harambat J (2016) Mycophenolic acid pharmacokinetics and relapse in children with steroid-dependent idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 11:1777\u20131782. https:\/\/doi.org\/10.2215\/CJN.00320116","journal-title":"Clin J Am Soc Nephrol"},{"key":"5520_CR88","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/FTD.0000000000000258","volume":"38","author":"\u00c1 Hackl","year":"2016","unstructured":"Hackl \u00c1, Cseprek\u00e1l O, Gessner M, Liebau MC, Habbig S, Ehren R, M\u00fcller C, Taylan C, D\u00f6tsch J, Weber LT (2016) Mycophenolate mofetil therapy in children with idiopathic nephrotic syndrome. Ther Drug Monit 38:274\u2013279. https:\/\/doi.org\/10.1097\/FTD.0000000000000258","journal-title":"Ther Drug Monit"},{"key":"5520_CR89","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ejps.2015.06.017","volume":"77","author":"J Sobiak","year":"2015","unstructured":"Sobiak J, Resztak M, Ostalska-Nowicka D, Zachwieja J, G\u0105siorowska K, Piechanowska W, Chrzanowska M (2015) Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters. Eur J Pharm Sci 77:189\u2013196. https:\/\/doi.org\/10.1016\/j.ejps.2015.06.017","journal-title":"Eur J Pharm Sci"},{"key":"5520_CR90","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","volume":"97","author":"EY Chan","year":"2020","unstructured":"Chan EY, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Ma AL, Yamamura T, Sinha A, Bagga A, Hogan J, Dossier C, Vivarelli M, Liu ID, Kamei K, Ishikura K, Saini P, Tullus K (2020) Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int 97:393\u2013401. https:\/\/doi.org\/10.1016\/j.kint.2019.09.033","journal-title":"Kidney Int"},{"key":"5520_CR91","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12882-019-1470-3","volume":"20","author":"C Nagano","year":"2019","unstructured":"Nagano C, Sako M, Kamei K, Ishikura K, Nakamura H, Nakanishi K, Omori T, Nozu K, Iijima K (2019) Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial). BMC Nephrol 20:293. https:\/\/doi.org\/10.1186\/s12882-019-1470-3","journal-title":"BMC Nephrol"},{"key":"5520_CR92","doi-asserted-by":"publisher","first-page":"35","DOI":"10.7326\/m18-3667","volume":"172","author":"DM Kent","year":"2020","unstructured":"Kent DM, Paulus JK, van Klaveren D, D\u2019Agostino R, Goodman S, Hayward R, Ioannidis JPA, Patrick-Lake B, Morton S, Pencina M, Raman G, Ross JS, Selker HP, Varadhan R, Vickers A, Wong JB, Steyerberg EW (2020) The Predictive Approaches to Treatment effect Heterogeneity (PATH) statement. Ann Intern Med 172:35\u201345. https:\/\/doi.org\/10.7326\/m18-3667","journal-title":"Ann Intern Med"},{"key":"5520_CR93","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1053\/j.ajkd.2013.10.043","volume":"63","author":"JK Inrig","year":"2014","unstructured":"Inrig JK, Califf RM, Tasneem A, Vegunta RK, Molina C, Stanifer JW, Chiswell K, Patel UD (2014) The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov. Am J Kidney Dis 63:771\u2013780. https:\/\/doi.org\/10.1053\/j.ajkd.2013.10.043","journal-title":"Am J Kidney Dis"},{"key":"5520_CR94","unstructured":"U.S. Food and Drug Administration (2019) Enrichment strategies for clinical trials to support determination of effectiveness of human drugs and biological products. Guidance for Industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enrichment-strategies-clinical-trials-support-approval-human-drugs-and-biological-products"},{"key":"5520_CR95","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s004670050224","volume":"11","author":"M Konrad","year":"1997","unstructured":"Konrad M, Mytilineos J, Ruder H, Opelz G, Sch\u00e4rer K (1997) HLA-DR7 predicts the response to alkylating agents in steroid-sensitive nephrotic syndrome. Pediatr Nephrol 11:16\u201319. https:\/\/doi.org\/10.1007\/s004670050224","journal-title":"Pediatr Nephrol"},{"key":"5520_CR96","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.10.004","author":"JB Hodgin","year":"2021","unstructured":"Hodgin JB, Mariani LH, Zee J, Liu Q, Smith AR, Eddy S, Hartman J, Hamidi H, Gaut JP, Palmer MB, Nast CC, Chang A, Hewitt S, Gillespie BW, Kretzler M, Holzman LB, Barisoni L (2021) Quantification of glomerular structural lesions: associations with clinical outcomes and transcriptomic profiles in nephrotic syndrome. Am J Kidney Dis. https:\/\/doi.org\/10.1053\/j.ajkd.2021.10.004","journal-title":"Am J Kidney Dis"},{"key":"5520_CR97","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/ki.2012.428","volume":"83","author":"CA Gadegbeku","year":"2013","unstructured":"Gadegbeku CA, Gipson DS, Holzman LB, Ojo AO, Song PXK, Barisoni L, Sampson MG, Kopp JB, Lemley KV, Nelson PJ, Lienczewski CC, Adler SG, Appel GB, Cattran DC, Choi MJ, Contreras G, Dell KM, Fervenza FC, Gibson KL, Greenbaum LA, Hernandez JD, Hewitt SM, Hingorani SR, Hladunewich M, Hogan MC, Hogan SL, Kaskel FJ, Lieske JC, Meyers KEC, Nachman PH, Nast CC, Neu AM, Reich HN, Sedor JR, Sethna CB, Trachtman H, Tuttle KR, Zhdanova O, Zilleruelo GE, Kretzler M (2013) Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int 83:749\u2013756. https:\/\/doi.org\/10.1038\/ki.2012.428","journal-title":"Kidney Int"},{"key":"5520_CR98","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12882-019-1320-3","volume":"20","author":"SM Samuel","year":"2019","unstructured":"Samuel SM, Dart A, Filler G, Bitzan M, Pinsk M, Mammen C, Nettel-Aguirre A, Perinpanayagam MA, Takano T, Chanchlani R, Zappitelli M (2019) The Canadian childhood nephrotic syndrome (CHILDNEPH) study: report on mid-study feasibility, recruitment and main measures. BMC Nephrol 20:159. https:\/\/doi.org\/10.1186\/s12882-019-1320-3","journal-title":"BMC Nephrol"},{"key":"5520_CR99","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2369-14-25","volume":"14","author":"N Hussain","year":"2013","unstructured":"Hussain N, Zello JA, Vasilevska-Ristovska J, Banh TM, Patel VP, Patel P, Battiston CD, Hebert D, Licht CP, Piscione TD, Parekh RS (2013) The rationale and design of insight into nephrotic syndrome: investigating genes, health and therapeutics (INSIGHT): a prospective cohort study of childhood nephrotic syndrome. BMC Nephrol 14:25. https:\/\/doi.org\/10.1186\/1471-2369-14-25","journal-title":"BMC Nephrol"},{"key":"5520_CR100","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","volume":"18","author":"Adaptive Platform Trials Coalition","year":"2019","unstructured":"Adaptive Platform Trials Coalition (2019) Adaptive platform trials: definition, design, conduct and reporting considerations. Nat Rev Drug Discov 18:797\u2013807. https:\/\/doi.org\/10.1038\/s41573-019-0034-3","journal-title":"Nat Rev Drug Discov"},{"key":"5520_CR101","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1510062","volume":"377","author":"J Woodcock","year":"2017","unstructured":"Woodcock J, LaVange LM (2017) Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med 377:62\u201370. https:\/\/doi.org\/10.1056\/NEJMra1510062","journal-title":"N Engl J Med"},{"key":"5520_CR102","doi-asserted-by":"publisher","DOI":"10.1007\/s40199-021-00430-8","author":"PC Lim","year":"2022","unstructured":"Lim PC, Wong KL, Rajah R, Chong MF, Chow TS, Subramaniam S, Lee CY (2022) Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis. Daru. https:\/\/doi.org\/10.1007\/s40199-021-00430-8","journal-title":"Daru"},{"key":"5520_CR103","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/s0140-6736(21)00676-0","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397:1637\u20131645. https:\/\/doi.org\/10.1016\/s0140-6736(21)00676-0","journal-title":"Lancet"},{"key":"5520_CR104","unstructured":"RECOVERY Collaborative Group, Horby PW, Mafham M, Peto L, Campbell M, Pessoa-Amorim G, Spata E, Staplin N, Emberson JR, Prudon B, Hine P, Brown T, Green CA, Sarkar R, Desai P, Yates B, Bewick T, Tiberi S, Felton T, Baillie JK, Buch MH, Chappell LC, Day JN, Faust SN, Jaki T, Jeffery K, Juszczak E, Lim WS, Montgomery A, Mumford A, Rowan K, Thwaites G, Weinreich DM, Haynes R, Landray MJ (2021) Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. https:\/\/www.medrxiv.org\/content\/10.1101\/2021.06.15.21258542v1"},{"key":"5520_CR105","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.kint.2019.01.047","volume":"95","author":"SA Carter","year":"2019","unstructured":"Carter SA, Lightstone L, Cattran D, Bagga A, Barbour SJ, Barratt J, Boletis J, Caster D, Coppo R, Fervenza FC, Floege J, Hladunewich M, Hogan JJ, Kitching AR, Lafayette R, Malvar A, Radhakrishnan J, Rovin BH, Zhang H, Gutman T, Howell M, Logeman C, Shen JI, Teixeira-Pinto A, Alexander SI, Cho Y, Craig JC, Harris D, Johnson DW, Kerr PG, Ryan J, Viecelli AK, Wang AY, Wilkie M, Scholes-Robertson N, Tong A (2019) Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. Kidney Int 95:1280\u20131283. https:\/\/doi.org\/10.1016\/j.kint.2019.01.047","journal-title":"Kidney Int"},{"key":"5520_CR106","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s13063-016-1528-5","volume":"17","author":"A Tong","year":"2016","unstructured":"Tong A, Samuel S, Zappitelli M, Dart A, Furth S, Eddy A, Groothoff J, Webb NJ, Yap HK, Bockenhauer D, Sinha A, Alexander SI, Goldstein SL, Gipson DS, Hanson CS, Evangelidis N, Crowe S, Harris T, Hemmelgarn BR, Manns B, Gill J, Tugwell P, Van Biesen W, Wheeler DC, Winkelmayer WC, Craig JC (2016) Standardised Outcomes in Nephrology-Children and Adolescents (SONG-Kids): a protocol for establishing a core outcome set for children with chronic kidney disease. Trials 17:401. https:\/\/doi.org\/10.1186\/s13063-016-1528-5","journal-title":"Trials"},{"key":"5520_CR107","doi-asserted-by":"publisher","first-page":"e0230824","DOI":"10.1371\/journal.pone.0230824","volume":"15","author":"KE Faulk","year":"2020","unstructured":"Faulk KE, Anderson-Mellies A, Cockburn M, Green AL (2020) Assessment of enrollment characteristics for Children\u2019s Oncology Group (COG) upfront therapeutic clinical trials 2004\u20132015. PLoS One 15:e0230824\u2013e0230824. https:\/\/doi.org\/10.1371\/journal.pone.0230824","journal-title":"PLoS ONE"},{"key":"5520_CR108","unstructured":"American Cancer Society (2022 ) Key statistics for childhood cancers. https:\/\/www.cancer.org\/cancer\/cancer-in-children\/key-statistics.html. Accessed 28 January 2022"},{"key":"5520_CR109","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/s0140-6736(17)30788-2","volume":"390","author":"A Levin","year":"2017","unstructured":"Levin A, Tonelli M, Bonventre J, Coresh J, Donner JA, Fogo AB, Fox CS, Gansevoort RT, Heerspink HJL, Jardine M, Kasiske B, K\u00f6ttgen A, Kretzler M, Levey AS, Luyckx VA, Mehta R, Moe O, Obrador G, Pannu N, Parikh CR, Perkovic V, Pollock C, Stenvinkel P, Tuttle KR, Wheeler DC, Eckardt KU (2017) Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet 390:1888\u20131917. https:\/\/doi.org\/10.1016\/s0140-6736(17)30788-2","journal-title":"Lancet"},{"key":"5520_CR110","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.kint.2020.10.048","volume":"99","author":"RDR Evans","year":"2021","unstructured":"Evans RDR, Smyth B, Levin A, Jha V, Wheeler DC, Jardine M, Perkovic V, Damster S, Malik C, de Zeeuw D, Hiemstra T (2021) The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) network: current activities and future goals. Kidney Int 99:551\u2013554. https:\/\/doi.org\/10.1016\/j.kint.2020.10.048","journal-title":"Kidney Int"},{"key":"5520_CR111","doi-asserted-by":"publisher","first-page":"k4738","DOI":"10.1136\/bmj.k4738","volume":"363","author":"JC Crocker","year":"2018","unstructured":"Crocker JC, Ricci-Cabello I, Parker A, Hirst JA, Chant A, Petit-Zeman S, Evans D, Rees S (2018) Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis. BMJ 363:k4738","journal-title":"BMJ"},{"key":"5520_CR112","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/j.1369-7625.2012.00795.x","volume":"17","author":"J Brett","year":"2014","unstructured":"Brett J, Staniszewska S, Mockford C, Herron-Marx S, Hughes J, Tysall C, Suleman R (2014) Mapping the impact of patient and public involvement on health and social care research: a systematic review. Health Expect 17:637\u2013650. https:\/\/doi.org\/10.1111\/j.1369-7625.2012.00795.x","journal-title":"Health Expect"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05520-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-022-05520-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05520-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:05:37Z","timestamp":1744200337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-022-05520-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":112,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["5520"],"URL":"https:\/\/doi.org\/10.1007\/s00467-022-05520-6","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"assertion":[{"value":"8 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rulan Parekh is the principal investigator for the INSIGHT study. Ashlene McKay and Damien Noone declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}